Intellectus Partners LLC Reduces Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Intellectus Partners LLC trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,235 shares of the medical equipment provider’s stock after selling 275 shares during the quarter. Intellectus Partners LLC’s holdings in Intuitive Surgical were worth $1,766,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. WCM Investment Management LLC acquired a new stake in Intuitive Surgical in the fourth quarter worth approximately $575,536,000. International Assets Investment Management LLC increased its holdings in shares of Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after buying an additional 684,749 shares in the last quarter. Alphinity Investment Management Pty Ltd increased its holdings in shares of Intuitive Surgical by 113.2% in the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after buying an additional 677,455 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new position in shares of Intuitive Surgical in the third quarter valued at $178,667,000. Finally, Quadrature Capital Ltd increased its holdings in shares of Intuitive Surgical by 466.2% in the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after buying an additional 280,480 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ISRG. Truist Financial upped their price target on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. BTIG Research boosted their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Stifel Nicolaus boosted their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded up $2.21 during trading hours on Friday, reaching $375.33. The company’s stock had a trading volume of 927,845 shares, compared to its average volume of 1,564,565. The company has a market cap of $133.13 billion, a price-to-earnings ratio of 67.75, a price-to-earnings-growth ratio of 4.85 and a beta of 1.36. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The business’s 50-day moving average is $386.19 and its 200-day moving average is $346.29.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.00 earnings per share. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now directly owns 1,842 shares in the company, valued at $736,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares in the company, valued at $9,385,753.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The disclosure for this sale can be found here. Over the last three months, insiders sold 249,418 shares of company stock worth $96,300,959. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.